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The year 2020 will undoubtedly be remembered for the COVID‐19 (SARS‐CoV‐2) pandemic. The ramifications from this viral pandemic are huge. There has been massive disruption to health care and the economies from almost every country in the world owing to the need to cope with the increased use of hospital beds and to contain the spread of this infection by the use of social restriction. In the UK, virtually all elective health care has come to a standstill in order to deal with the increased hospital admissions due to COVID‐19. Even the treatment of patients with cancer has also been affected owing to the need to shield such patients from the immunosuppressive effects of their cancer treatment. We have also seen that prolonged measures of social restriction are associated with various psychological issues in the community.

The first reported presence of this virus was from Wuhan in China in December 2019. Since then, the pandemic has spread to other countries in the Far East and subsequently to Europe, North America and elsewhere. It is now clear that without an effective vaccine and treatment for this infection, the virus is likely to remain prevalent. So far, it is unlikely that a vaccine or treatment will be available in the immediate future. Adaptation to health services is probably going to be required for some significant length of time in order to avoid any secondary peaks in new infections.

*BJOG* has been striving to report on scientific articles relating to COVID‐19 in order to guide obstetricians and gynaecologists in the management of patients with this infection and also in how to control the pandemic. The publication of several related articles has been fast tracked. A Commentary on obstetric measures taken in Singapore to control this infection has been published previously (Chua et al. *BJOG* 2020;127:786--88). In this issue, Qi et al. (pages 927--29) also report their experience from China. The timing of delivery should be decided based on maternal disease status and whether there is any other obstetric indication to expedite the delivery. There is no clear evidence on whether a vaginal or abdominal delivery is more beneficial, and both regional and general anaesthesia can be employed during labour and delivery. The use of general anaesthesia is now considered to be an aerosol generating procedure and hence would require full personal protective equipment (PPE). It is also clear that delivery among women with proven COVID‐19 infections should be undertaken in an isolated delivery suite with staff using full PPE. There is increasing evidence that vertical viral transmission is possible and hence umbilical blood, amniotic fluid, placental and neonatal throat/nasal swabs should be obtained for monitoring of the newborn infant. At the time of writing, there are three more articles on COVID‐19 disease in pregnant women that have been published online. The first two are an article based on the experience of managing this disease in Northern Italy (Ferrazzi et al. *BJOG* 2020; <https://doi.org/10.1111/1471-0528.16278>) and another case series from China on the safety of vaginal delivery and breastfeeding (Wu et al. *BJOG* 2020; <https://doi.org/10.1111/1471-0528.16276>). The remaining article is an updated Commentary from China on how to treat due to pregnant women infected with SARS‐CoV‐2 (Faure‐Bardon et al. *BJOG* 2020; <https://doi.org/10.1111/1471-0528.16270>). As more information is available, there will be further publications available on this disease to guide clinical care. We have also created a BJOG COVID‐19 Resource Centre (available at <https://obgyn.onlinelibrary.wiley.com/hub/journal/14710528/covid-19_resource_centre>), which is a compilation of relevant clinical guidelines and statements from professional societies, COVID‐19 registries, primary research and systematic reviews, as well as interesting websites and blogs.

The pandemic has also indirectly affected gynaecology practice. Although elective gynaecology has virtually ceased in the UK at the time of writing, emergency gynaecological and some elements of cancer surgery are still ongoing. It is also evident that patients contracting COVID‐19 infection during surgery are more likely to experience increased post‐operative morbidity and mortality. There is therefore an increasing trend to employ more conservative treatments where possible, such as the use of the Mirena intrauterine system (IUS) to treat dysfunctional uterine bleeding and vaginal pessary for genital tract prolapse. On pages 957--65, Mandelbaum et al. report the increased use of conservative surgery instead of the more conventional treatment with oophorectomy for ovarian torsion in the USA, especially in younger patients, without any increase in perioperative complications. Conservative surgery is defined as any ovarian detorsion with or without ovarian cystectomy, drainage of ovarian cyst or oophoropexy. Progestogens such as the Mirena IUS have also been successfully used to treat low‐grade endometrial carcinoma (Pal et al. *Obstet Gynecol* 2018;131:109--16). On page 1001, Barr and Crosbie argue for the use of the Mirena IUS to treat early‐stage endometrial cancer in obese women in whom surgery with laparoscopic total hysterectomy and bilateral salpingo‐oophorectomy may be technically challenging, with Farthing (page 1000) providing the counter response to this debate. Although these studies on the use of conservative surgery for ovarian torsion and Mirena IUS for early‐stage endometrial carcinoma were undertaken outside of a pandemic setting, the use of such treatments may be helpful to health services around the world to cope with this disease.
